
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. exhibits a strong positive outlook due to significant year-over-year growth in its product lines, with sales of surgical soft tissue repair products reaching $23.4 million, reflecting a 24% increase driven by heightened demand for CellerateRX Surgical and BIASURGE. Additionally, the company reported a robust 28% increase in revenue for soft tissue repair products, further supporting its growth trajectory in the surgical segment. The strategic initiatives to expand distribution networks and penetrate additional healthcare facilities are expected to sustain this momentum, coupled with the notable achievement of profitability in continuing operations anticipated for the third quarter of 2025.
Bears say
Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a 21.5% year-over-year growth that fell slightly short of projections, raising concerns about its revenue growth trajectory. Key risks identified include the potential for lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products or services, and risks of equity dilution. Additionally, the company's valuation has been revised downwards, with the EV/Revenue multiple decreasing from 4.3x to 3.0x following the strategic decision to exclude telehealth from its business model.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares